International Cholangiocarcinoma Research Network (ICRN)

The ICRN is a global collaboration of research groups from renowned institutions that are working in concert to improve knowledge about cholangiocarcinoma etiology, prevention, early detection, treatment and prognosis. The network is comprised of highly talented individuals from a spectrum of disciplines, perspectives, and research methods who share the passion to make significant scientific advances that improve outcomes for patients with cholangiocarcinoma.

The goal of ICRN is to accelerate the clinical translation of scientific discoveries to impact the lives of patients with cholangiocarcinoma.

ICRN Newsletters

ICRN Members Map

If your industry or biotech company or organization is interested in partnering with the ICRN for the purposes of cholangiocarcinoma research and potential collaboration, please fill out the ICRN Industry Request for Engagement form.

ICRN Executive Committee


Milind Javle, MD


UT MD Anderson Cancer Center

Mitesh Borad, MD

Vice Chair

Mayo Clinic, Arizona


John Bridgewater, PhD

University College London Hospital, UK


Yun Shin Chun, MD, FACS

MD Anderson


Laura Goff, MD

Vanderbilt Ingram Cancer Center

Lipika Goyal

Lipika Goyal, MD

Massachusetts General Hospital/Harvard University

Stacie Lindsey

Stacie Lindsey

Cholangiocarcinoma Foundation


Shishir K. Maithel, MD, FACS

Emory University


Lewis Roberts, MB, ChB, PhD

Mayo Clinic, Minnesota


Flavio Rocha, MD, FACS

Virginia Mason Medical Center


Virote Sriuranpong, MD, PhD

Chulalongkorn University

The ICRN and CCF are here to help!

CCF and the ICRN are here to help support your research and clinical trial efforts to benefit patients with cholangiocarcinoma. Please contact if you would like information regarding:

  • Posting any trial open to cca patients (including baskets, pan-tumor, solid tumor, etc.) on CCF’s website and social media
  • Hosting a patient education webinar about your trial
  • Assistance with clinical validation of your agent in cholangiocarcinoma (IST’s, multi-institutional collaborations)
  • Assistance with pre-clinical validation of your agent in cholangiocarcinoma (access to cca cell lines, PDX models, tissues samples, etc.)
  • Patient Advisory Boards
  • Industry Forum presentation opportunities to 50+ KOL’s
  • US and Asia-Pacific Poster, Exhibit and Sponsorship opportunities
  • Patient and caregiver speakers and advocates
  • Telecons with KOL’s to discuss trial design and protocols
  • and more

Advocacy Organization Hybrid Model for Advancing Research

Translate »

Pin It on Pinterest